The Absolute Effect / Evidence index
Advanced / Metastatic · Phase III open-label randomized; N=299; first-line dMMR advanced/recurrent endometrial cancer. Pembrolizumab vs carboplatin-paclitaxel. Dual primary endpoints BICR PFS and OS. · Median PFS 38.2 vs 8.4 months
KEYNOTE-C93 / GOG-3064 / ENGOT-en15
Clinical question: In first-line dMMR advanced or recurrent endometrial cancer, is pembrolizumab monotherapy superior to carboplatin-paclitaxel?
Median PFS 38.2 vs 8.4 months; HR 0.57 (95% CI 0.42–0.79; P=0.0002). 12-month PFS 67% vs 40% (NNT 4). OS boundary not met (HR 0.77; P=0.10). · Registry:
Design, population and treatment
Phase III open-label randomized; N=299; first-line dMMR advanced/recurrent endometrial cancer. Pembrolizumab vs carboplatin-paclitaxel. Dual primary endpoints BICR PFS and OS.
Key efficacy outcome
Grade ≥3 treatment-related AEs 18% vs 51%; treatment-related discontinuation 9% vs 15%.
Safety and absolute effect
12-month PFS (%)
https://pubmed.ncbi.nlm.nih.gov/42933458/
Interpretation and limitations
Current-practice context · 14 November 2026: Primary publication/abstract and trial identifier checked. Guideline-level current-practice mapping was not established in this publication-led batch; no NCCN citation provenance is claimed. Where detailed QoL, follow-up or toxicity data were not present in the retrieved abstract, they are not inferred.